Recombinant human HER2 monoclonal antibody - Anhui Anke Biotechnology
Latest Information Update: 22 Nov 2016
At a glance
- Originator Anhui Anke Biotechnology
- Developer Anhui Anke Biotechnology; Peking University People's Hospital
- Class Monoclonal antibodies
- Mechanism of Action ERBB 2 receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Breast cancer
Most Recent Events
- 08 Apr 2016 Phase-I clinical trials in Breast cancer (In volunteers) in China (unspecified route) (ChiCTR-IIR16009808)